O
8.99
-0.16 (-1.70%)
| Previous Close | 9.14 |
| Open | 9.12 |
| Volume | 2,281,341 |
| Avg. Volume (3M) | 5,764,256 |
| Market Cap | 2,335,704,576 |
| Price / Earnings (TTM) | 3.12 |
| Price / Sales | 0.450 |
| Price / Book | 6.08 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| TTM Dividend Yield | 12.47% |
| Profit Margin | 13.49% |
| Operating Margin (TTM) | 18.72% |
| Diluted EPS (TTM) | 3.33 |
| Quarterly Revenue Growth (YOY) | -0.40% |
| Quarterly Earnings Growth (YOY) | -80.00% |
| Total Debt/Equity (MRQ) | 1,914.41% |
| Current Ratio (MRQ) | 1.60 |
| Operating Cash Flow (TTM) | 939.00 M |
| Levered Free Cash Flow (TTM) | 569.00 M |
| Return on Assets (TTM) | 7.39% |
| Return on Equity (TTM) | 429.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bearish | Mixed |
| Drug Manufacturers - General (Global) | Bearish | Mixed | |
| Stock | Organon & Co. | Bearish | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.0 |
| Insider Activity | 1.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -4.0 |
| Average | 0.00 |
|
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Small Value |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 83.00% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Piper Sandler, 100.33%) | Buy |
| Median | 14.00 (55.82%) | |
| Low | 10.00 (Morgan Stanley, 11.30%) | Hold |
| Average | 14.00 (55.82%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 8.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 15 May 2025 | 18.00 (100.33%) | Buy | 8.77 |
| Morgan Stanley | 05 May 2025 | 10.00 (11.30%) | Hold | 8.72 |
| 09 Apr 2025 | 15.00 (66.94%) | Hold | 12.64 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Organon Reports Results for the First Quarter Ended March 31, 2025 |
| 15 Apr 2025 | Announcement | Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 |
| 15 Apr 2025 | Announcement | Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors |
| 01 Apr 2025 | Announcement | Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. |
| 28 Mar 2025 | Announcement | European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 |
| 08 Mar 2025 | Announcement | New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older |
| TTM Dividend Yield | 12.47% |
| 4Y Average Dividend Yield | 5.53% |
| Payout Ratio | 33.63% |
| Expected Next Dividend Payment | Jun 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 24 Feb 2025 | 13 Feb 2025 | 13 Mar 2025 | 0.28 Cash |
| 12 Nov 2024 | 31 Oct 2024 | 12 Dec 2024 | 0.28 Cash |
| 16 Aug 2024 | 06 Aug 2024 | 12 Sep 2024 | 0.28 Cash |
| 10 May 2024 | 02 May 2024 | 13 Jun 2024 | 0.28 Cash |
| 23 Feb 2024 | 15 Feb 2024 | 14 Mar 2024 | 0.28 Cash |
| 10 Nov 2023 | 02 Nov 2023 | 14 Dec 2023 | 0.28 Cash |
| 17 Aug 2023 | 08 Aug 2023 | 14 Sep 2023 | 0.28 Cash |
| 12 May 2023 | 04 May 2023 | 15 Jun 2023 | 0.28 Cash |
| 24 Feb 2023 | 16 Feb 2023 | 16 Mar 2023 | 0.28 Cash |
| 11 Nov 2022 | 03 Nov 2022 | 15 Dec 2022 | 0.28 Cash |
| 10 Nov 2022 | 03 Nov 2022 | 15 Dec 2022 | 0.28 Cash |
| 12 Aug 2022 | 04 Aug 2022 | 15 Sep 2022 | 0.28 Cash |
| 13 May 2022 | 05 May 2022 | 16 Jun 2022 | 0.28 Cash |
| 25 Feb 2022 | 17 Feb 2022 | 17 Mar 2022 | 0.28 Cash |
| 19 Nov 2021 | 11 Nov 2021 | 16 Dec 2021 | 0.28 Cash |
| 20 Aug 2021 | 12 Aug 2021 | 13 Sep 2021 | 0.28 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.280 | 1 | 3.12 |
| 2024 | 1.12 | 4 | 7.51 |
| 2023 | 1.12 | 4 | 7.77 |
| 2022 | 1.40 | 5 | 5.01 |
| 2021 | 0.560 | 2 | 1.84 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |